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Introduction
Sclerotic graft-versus-host disease (GVHD) represents a distinctive phenotype of chronic GVHD first described in 1977, 1 often associated with severe disability and morbidity after allogeneic hematopoietic cell transplantation (HCT). 2 While sclerotic GVHD has some clinical and histopathological similarities with systemic sclerosis, the pathogenic mechanisms of the two diseases are thought to differ. 3, 4 Systemic sclerosis can involve visceral organs with pulmonary hypertension, renal dysfunction and cardiac dysfunction, whereas these manifestations are rarely observed in patients with sclerotic GVHD. 2, 3 Systemic sclerosis begins in deeper layers of the skin and then extends to superficial layers, whereas sclerotic GVHD usually begins in superficial layers of the skin and then extends to deeper layers. 2, 4 Systemic sclerosis often presents with vasculopathy and Raynaud's phenomenon, 3 whereas sclerotic GVHD rarely presents with these manifestations, 2, 4 although endothelial injury associated with chronic GVHD has been observed in some studies. 5 To date, reports describing sclerosis among patients with chronic GVHD have been limited to small series and one larger cross-sectional study of single patient visits for an evaluation of relatively severe chronic GVHD. [6] [7] [8] The incidence of sclerotic GVHD, risk factors for sclerotic GVHD and its association with major transplant outcomes have not been well defined. While chronic GVHD occurs in 40-50% of patients after HCT, some develop sclerosis during the clinical course of chronic GVHD but others do not. In a large cohort of consecutive patients treated with systemic immunosuppression for chronic GVHD, we aimed to elucidate (1) the overall incidence of sclerosis, (2) risk factors for sclerosis, and (3) potential differences in transplant outcomes after patients develop sclerosis. Better understanding of risk factors would help to identify candidates for early interventional studies aimed at reducing disability related to sclerosis after HCT.
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Methods

Patients
We identified all patients who received initial systemic treatment for chronic GVHD after a first Alliance. Patients who received a double cord blood transplantation were excluded, since the interpretation of donor-related factors such as gender combination, HLA matching and ABO matching in this setting is complex. 9 Patients who had recurrent malignancy before the onset of chronic GVHD were excluded, since immunosuppressive treatment might have been modified in order to enhance graft-versus-tumor effect after recurrent malignancy. Patients had given written consent allowing the use of medical records for research in accordance with the Declaration of Helsinki, and the institutional review board approved the study.
Clinical assessments and definitions
Acute GVHD was graded according to previously described criteria. 10 Chronic GVHD was diagnosed by the NIH consensus criteria. 11 Information about chronic GVHD and follow-up outcomes were captured prospectively by the Long-Term Follow-Up program through medical records from our outpatient clinic and local clinics providing the primary care of patients.
12
Sclerotic GVHD was defined when manifestations of cutaneous sclerosis, fasciitis or joint contracture were first documented in the medical record. A comprehensive retrospective chart review was performed to identify an accurate onset date and manifestations of sclerotic GVHD.
HLA typing of donor and recipient pairs was performed using methods informative for the highest resolution of alleles available at the time of the analysis. Recipient HLA-mismatching was defined when a recipient had at least one HLA-A, B, C, DRB1 or DQB1 antigen or allele that were not present in the donor (i.e., GVHD vector mismatching).
Statistical analysis
The primary endpoint was sclerosis at any time among all patients with chronic GVHD included in the study. The cumulative incidence of sclerosis was estimated from the initial systemic treatment of chronic GVHD, treating recurrent malignancy and death without sclerosis as competing risks. 13 Cox regression analyses were used to identify risk factors for sclerosis. The and thrombocytopenia (<100 000/μL), and progressive onset (i.e., direct progression from acute GVHD to chronic GVHD or onset of chronic GVHD during steroid treatment As secondary endpoints, overall mortality, nonrelapse mortality (malignant disease only), recurrent malignancy (malignant disease only) and end of systemic immunosuppressive treatment were compared between chronic GVHD patients with and without sclerosis, treating all sclerosis at any time as a time-dependent risk factor. Hazard ratios were adjusted for covariates associated with overall mortality in previous studies. 12, 14 The analysis was carried out as of July 2012.
Results
Patient characteristics and incidence of sclerosis in patients with chronic GVHD
We identified 1064 consecutive patients who received initial systemic treatment for chronic patients who had sclerosis after initial treatment. Overall, among 210 patients who developed sclerosis, 28 (13%) had only skin sclerosis, 70 (33%) had only joint contracture or fasciitis, and
Risk factors for sclerosis
In multivariate analyses ( In a separate analysis, we compared chronic GVHD-related characteristics at the initial systemic treatment of chronic GVHD between patients with and without sclerosis at the onset of systemic treatment. Eosinophilia was more frequently observed among the 70 patients with sclerosis as compared to the 907 patients without sclerosis at the onset of systemic treatment (46% vs. 14%, P <.0001). Thrombocytopenia and progressive onset were less frequently observed among patients with sclerosis as compared to those without sclerosis (11% vs. 34%, P <.0001 and 11% vs. 36%, P <.0001, respectively). In a separate Cox model, we examined chronic GVHD-related characteristics at the initial systemic treatment as potential predictive factors for subsequent development of sclerosis, among the 907 patients who did not have sclerosis at the onset of systemic treatment. None of the chronic GVHD-related characteristics was associated with the subsequent development of sclerosis.
For
Associations of sclerosis with transplant outcomes
Associations of sclerosis at any time with transplant outcomes were examined in all patients with chronic GVHD, treating development of sclerosis as a time-dependent risk factor (Table 3) .
Covariates associated with overall mortality in multivariate analyses were used for adjustment, including <5 months from HCT to initial systemic treatment of chronic GVHD as compared to 
Discussion
We found a substantial incidence of sclerosis after allogeneic HCT in a cohort of consecutive patients with chronic GVHD. The incidence of sclerosis reached 20% at 3 years after the initial systemic treatment of chronic GVHD, which was higher than the 10% to 15% rates reported in previous series. 6, 7 A single-visit cross-sectional study reported that the prevalence of sclerosis was 53% in a cohort of 206 patients with relatively severe chronic GVHD evaluated at the NIH Clinical Center. 8 Our study showed that one third of patients with sclerosis presented with this feature at the initial systemic treatment of chronic GVHD. The presence of sclerosis at initial treatment of chronic GVHD was associated with eosinophilia and less frequent thrombocytopenia, consistent with other reports, 7, 8 but none of chronic GVHD-related characteristics was associated with subsequent development of sclerosis.
We identified 4 patient or transplant-related factors associated with the risk of sclerosis among patients with chronic GVHD: use of a mobilized blood cell graft, conditioning with TBI >450 cGy, HLA mismatch and ABO mismatch. The protective association of HLA mismatching was counterintuitive, given the positive association of HLA mismatching as a risk factor for chronic GVHD. 15 The use of an unrelated donor, older patient age, use of a female donor for a male recipient, and prior acute GVHD were not identified as risk factors for sclerosis in the current study, although they are well-recognized risk factors for chronic GVHD. [15] [16] [17] [18] [19] [20] These results suggest that the profile of risk factors associated with sclerosis differs from the profile associated with chronic GVHD.
The protective effect of HLA-mismatching was not caused by higher early mortality, since HLA-mismatching was not associated with overall mortality in our cohort. Moreover, early mortality due to competing risks does not affect the hazard ratio, which reflects the relative probability of mortality among patients actually at risk throughout the entire time of observation.
For personal use only. on September 24, 2017. by guest www.bloodjournal.org From This consideration represents the primary motivation for using hazard ratio analysis, as opposed to analysis of incidence. 21 Mechanisms that might explain the reduced risk of sclerosis associated with HLA mismatching remain speculative. For example, HLA mismatching could have an immunodominant effect that blocks the development of fibrogenic donor T cell responses against "sclerogenic" minor antigens derived from connective tissues in the recipient. If fact, Amir et al. reported that responses to minor histocompatibility antigens were not generated in the presence of stimulation by mismatched major histocompatibility (MHC) antigens after HLAmismatched HCT. 22 In murine models, cutaneous sclerosis has been reported as a manifestation of GVHD after MHC-identical, minor antigen-mismatched HCT with cells from B10-strain donors to certain BALB-strain recipients. 23 Further work will be needed to confirm whether introducing an MHC mismatching in these murine models abrogates the development of sclerosis.
Many studies have shown that the use of mobilized blood cell graft is associated with an increased risk of chronic GVHD. 15, 24 Our results showed that the use of mobilized blood cell graft was also associated with an increased risk of sclerosis, fitting with the recent study showing that stem cell mobilization with granulocyte colony stimulating factor promoted murine sclerotic GVHD by inducing type 17 differentiation of T cells. 25 Besides, associations of serum IL-17 concentrations with disease severity of systemic sclerosis were observed. 26 Prior TBI exposure was more frequent among patients with sclerosis than among those without sclerosis in a cross-sectional study. 8 Our study identified TBI exposure >450 cGy as a risk factor for sclerosis among patients with chronic GVHD. Irradiated skin is predisposed to cutaneous GVHD in humans. 27 In a murine model, mice grafted with irradiated syngeneic skin and injected with allogeneic lymphocytes developed skin GVHD in the irradiated graft, but not in non-irradiated grafts. 28 Irradiation may upregulate expression of MHC molecules and IFN-γ production in the skin. These effects, combined with epidermal damage and systemic cytokine production, might increase the risk of sclerosis.
We expected that development of sclerosis could have negative associations with survival outcomes. However, overall mortality, nonrelapse mortality and recurrent malignancy did not differ statistically between chronic GVHD patients with and without sclerosis, suggesting that sclerosis does not greatly affect the overall prognosis in patients with chronic GVHD. Sclerosis, nonetheless, is often associated with considerable disability and morbidity, and the prolonged duration of immunosuppressive treatment demonstrated in our study is likely to increase the risk of infections and other late complications.
Our study has some limitations. First, the incidence of sclerosis may be underestimated due to potential underreporting of sclerosis by local providers who may not be familiar with this manifestation of chronic GVHD. Second, available data did not allow further analysis regarding severity and extent of sclerosis, levels of disability, patient-reported parameters, quality of life measures, social recovery parameters, or any assessment of clinical response of sclerotic manifestations after treatment. Lastly, our results require careful interpretation because of multiple comparisons. For example, the association of HLA mismatching with a decreased risk of sclerosis was counterintuitive and the association of major ABO-mismatching with a decreased risk of sclerosis may be difficult to explain. Further studies are warranted to determine whether findings from the current study hold true.
In conclusion, we found a substantial incidence of sclerosis in patients with chronic GVHD.
Our findings are useful for counseling patients about sclerosis after HCT and may help to identify candidates for early interventional studies aimed to reduce disability related to sclerosis.
Furthermore, our findings will foster future studies of pathogenic mechanisms of sclerotic GVHD.
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